{"title":"네이버 금융 ─ 뉴스 ─ 실시간 속보","url":"https://finance.naver.com/news/news_list.naver?mode=LSS2D&section_id=101&section_id2=258","favicon":"https://finance.naver.com/news/favicon.ico","elements":[{"title":"[fn마켓워치]스틱, 베트남 아마존 '티키'에 베팅","contents":"<a href=\"/news/news_read.naver?article_id=0004739178&amp;office_id=014&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[fn마켓워치]스틱, 베트남 아마존 '티키'에 베팅\">[fn마켓워치]스틱, 베트남 아마존 '티키'에 베팅</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004739178&office_id=014&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258620},{"title":"[주간증시전망] 물가불안 속 테마 위주 종목장세 예상","contents":"<a href=\"/news/news_read.naver?article_id=0004739177&amp;office_id=014&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[주간증시전망] 물가불안 속 테마 위주 종목장세 예상\">[주간증시전망] 물가불안 속 테마 위주 종목장세 예상</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004739177&office_id=014&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258620},{"title":"[VC가 찜한 스타트업] 박서준·태연도 찾는 반려동물 플랫폼 '스파크펫'","contents":"<a href=\"/news/news_read.naver?article_id=0003984987&amp;office_id=011&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[VC가 찜한 스타트업] 박서준·태연도 찾는 반려동물 플랫폼 '스파크펫'\">[VC가 찜한 스타트업] 박서준·태연도 찾는 반려동물 플랫폼 '스파크펫'</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0003984987&office_id=011&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258626},{"title":"\"인내심에 한계\" 지지부진 주가에 동학개미, 삼성전자 손절","contents":"<a href=\"/news/news_read.naver?article_id=0000754190&amp;office_id=417&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"&quot;인내심에 한계&quot; 지지부진 주가에 동학개미, 삼성전자 손절\">\"인내심에 한계\" 지지부진 주가에 동학개미, 삼성전자 손절</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0000754190&office_id=417&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258626},{"title":"[표]코스닥 유무상증자 일정","contents":"<a href=\"/news/news_read.naver?article_id=0003984985&amp;office_id=011&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[표]코스닥 유무상증자 일정\">[표]코스닥 유무상증자 일정</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0003984985&office_id=011&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258626},{"title":"[표]유가증권 유무상증자 일정","contents":"<a href=\"/news/news_read.naver?article_id=0003984982&amp;office_id=011&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[표]유가증권 유무상증자 일정\">[표]유가증권 유무상증자 일정</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0003984982&office_id=011&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258626},{"title":"[마켓인]두산건설 팔린다…큐캐피탈-신영증권 컨소시엄","contents":"<a href=\"/news/news_read.naver?article_id=0005085706&amp;office_id=018&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"[마켓인]두산건설 팔린다…큐캐피탈-신영증권 컨소시엄\">[마켓인]두산건설 팔린다…큐캐피탈-신영증권 컨소시엄</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005085706&office_id=018&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258629},{"title":"SK바이오·카뱅...역대급 대어로 올해 IPO 공모액 20조원 돌파","contents":"<a href=\"/news/news_read.naver?article_id=0002981775&amp;office_id=030&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"SK바이오·카뱅...역대급 대어로 올해 IPO 공모액 20조원 돌파\">SK바이오·카뱅...역대급 대어로 올해 IPO 공모액 20조원 돌파</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0002981775&office_id=030&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258630},{"title":"500만주주, 7만전자에 지쳤다…개인 이달들어 2594억 매도","contents":"<a href=\"/news/news_read.naver?article_id=0004878733&amp;office_id=009&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"500만주주, 7만전자에 지쳤다…개인 이달들어 2594억 매도\">500만주주, 7만전자에 지쳤다…개인 이달들어 2594억 매도</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004878733&office_id=009&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258631},{"title":"'유럽 승인' 셀트리온 코로나 치료제, 경쟁약물 대비 부작용 적어","contents":"<a href=\"/news/news_read.naver?article_id=0000018488&amp;office_id=243&amp;mode=LSS2D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=&amp;date=20211114&amp;page=1\" title=\"'유럽 승인' 셀트리온 코로나 치료제, 경쟁약물 대비 부작용 적어\">'유럽 승인' 셀트리온 코로나 치료제, 경쟁약물 대비 부작용 적어</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0000018488&office_id=243&mode=LSS2D&type=0&section_id=101&section_id2=258&section_id3=&date=20211114&page=1","retrieved":1636866258636}]}